Influence of insulin resistance in obese patients on elevated serum alanine aminotransferase

European Review for Medical and Pharmacological Sciences

Volumn 11, Issue 1, 2007, Pages 21-25

  De Luis, Daniel A ^b   Aller, R ^a   Izaola, O ^b   Gonzalez Sagrado, M ^b   Conde, R ^b   Hernandez, Gonzalez ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Alanine aminotransferase; Determinants; Insulin resistance; Nonalcoholic fatty liver disease; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; REFERENCE VALUE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADULT; ALANINE TRANSAMINASE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; RISK FACTORS; TRIGLYCERIDES; WAIST-HIP RATIO;

EID: 33947703606     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiencies with a hitherto unnamed disease. Mayo Clinic Proc 1980; 55: 434-438.
2. Kral JG, Schaffner F, Pierson RN, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993; 42: 548-551.
3. Chitturi S, Abeygunasekera S, Farrel GC, Holmes-Walker J, Hui M, Fung C, Karim R. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379.
4. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thong SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-1517.
5. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
6. a.
7. Mataix J, Mañas M. Tablas de composición de alimentos españoles. Ed: University of Granada, 1998.
8. Marchesini G, Brizi M, Morselli-Labate A, Bianchi G, Bugianesi E, McCullough AJ. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-454.
9. Sanyal AJ, Campbell Sargent C, Mirshashi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
10. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30: 48-53.
11. Daniel S, Ben Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 3010-3014.
12. Venturi C, Zoppini G, Zamboni C, Muggeo M. Insulin sensivity and hepatic steatosis in obese subjects with normal glucose tolerance. Nutr Metab Cardiovasc Dis 2004; 14: 200-204.
13. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-152.
14. Yesilova Z, Ozata M, Oktenli C, Bagci S, Ozcan A. Increased acylation stimulating protein concentrations in noalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol 2005; 100: 842-849.
15. Carmiel-Haggai M, Cederbaum AI, Nieto N. A high fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 2005; 19: 136-138.
16. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894.
17. Lieber CS, Leo MA, Mak KM, Xu Y, Cao O, Ren C, Ponomarenko A, DeCarli LM. Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem Biophys Res Commun 2004; 315: 699-703.
18. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004; 20: 623-628.
19. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2003; 12: 189-192.